Clinical Trials
36 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
FOCUS
Ohio State University Comprehensive Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
LONGEVITI
University of Alberta
iCaRe2
University of Nebraska
CER
Cancer Support Community, Research and Training Institute, Philadelphia
SELECT-CAR-NK
Essen Biotech
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
LIBERATE
University Health Network, Toronto
DETERMINE
Cancer Research UK
ARC-12
Arcus Biosciences, Inc.
ROOT
Taproot Health
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
University of Pennsylvania
Mini-allo
Scripps Health
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
N1
CureOne
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Wake Forest University Health Sciences
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
BAY1238097, First in Man
Bayer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
IFNa
The Cleveland Clinic
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
SCRI Tissue Testing Registry
SCRI Development Innovations, LLC
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
M.D. Anderson Cancer Center
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center